Signals, Powered By EquityPandit
A subsidiary of Jubilant Life Science has signed long term contracts in the US to supply some of its diagnostic and therapeutic products.
Jubilant Life Sciences has said in a BSE filing that “Its wholly-owned subsidiary Jubilant Pharma, through one of its units, Jubilant Draxlmage Montreal Canada (JDI), has signed long-term contracts with distribution networks in the US for supply of products used for diagnostic and therapeutic procedures for thyroid, myocardial perfusion, lungs, kidney and bone scans to be supplied by JDI over 39 months effective January 2017.”
Shyam S Bhartia, the Chairman and Hari S Bhartia, the co-Chairman and MD of Jubilant Life Sciences has said that “These contracts provide visibility on our future revenues with differentiated and niche products in our specialty pharma business and will strengthen the company for its growth, going forward.”
